Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma

Fornecker, M; Muller, Leslie; Bertrand, Frédéric; Paul, Nicodème; Pichot, Angelique; Herbrecht, Raoul; Chenard, P; Mauvieux, Laurent; Vallat, Laurent; Bahram, Seiamak; Cianferani, Sarah; Carapito, Raphael; Carapito, Christine

doi:10.1038/s41598-018-37273-4

Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma

Citer cette référence

FORNECKER, Luc M., MULLER, Leslie, BERTRAND, Frédéric, PAUL, Nicodème, PICHOT, Angelique, HERBRECHT, Raoul, CHENARD, Marie Pierrette P., MAUVIEUX, Laurent, VALLAT, Laurent, BAHRAM, Seiamak, CIANFERANI, Sarah, CARAPITO, Raphael et CARAPITO, Christine, 2019. Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma. Scientific Reports [en ligne]. 2019. Vol. 9, n° 1. [Consultésans date]. DOI 10.1038/s41598-018-37273-4. Consulté de : https://www.ncbi.nlm.nih.gov/pubmed/306968901. . 2. .

Pas de texte intégral
Auteurs	Luc Fornecker Leslie Muller Frédéric Bertrand Nicodème Paul Angelique Pichot Raoul Herbrecht Marie Pierrette Chenard Laurent Mauvieux Laurent Vallat Seiamak Bahram Sarah Cianferani Raphael Carapito Christine Carapito
Unité de recherche du site	Interface Recherche Fondamentale et Appliquée en Cancérologie - IRFAC - UMRS1113 Institut Pluridisciplinaire Hubert Curien - IPHC - UMR7178 Institut de Recherche Mathématique Avancée - IRMA - UMR7501 Immuno-Rhumatologie moléculaire - IRM - UMRS1109 Institut de Génétique et de Biologie Moléculaire et Cellulaire - IGBMC - UMR7104
Langue	en
Volume	9
Numéro	1
Date de première publication	2019
Titre de la source (revue, livre…)	Scientific Reports
Résumé	The prognosis of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains unsatisfactory and, despite major advances in genomic studies, the biological mechanisms underlying chemoresistance are still poorly understood. We Show moreThe prognosis of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains unsatisfactory and, despite major advances in genomic studies, the biological mechanisms underlying chemoresistance are still poorly understood. We conducted for the first time a large-scale differential multi-omics investigation on DLBCL patient's samples in order to identify new biomarkers that could early identify patients at risk of R/R disease and to identify new targets that could determine chemorefractoriness. We compared a well-characterized cohort of R/R versus chemosensitive DLBCL patients by combining label-free quantitative proteomics and targeted RNA sequencing performed on the same tissues samples. The cross-section of both data levels allowed extracting a sub-list of 22 transcripts/proteins pairs whose expression levels significantly differed between the two groups of patients. In particular, we identified significant targets related to tumor metabolism (Hexokinase 3), microenvironment (IDO1, CXCL13), cancer cells proliferation, migration and invasion (S100 proteins) or BCR signaling pathway (CD79B). Overall, this study revealed several extremely promising biomarker candidates related to DLBCL chemorefractoriness and highlighted some new potential therapeutic drug targets. The complete datasets have been made publically available and should constitute a valuable resource for the future research. Show less
DOI	10.1038/s41598-018-37273-4
URL éditeur	https://www.ncbi.nlm.nih.gov/pubmed/30696890 internal-pdf://2891772625/fornecker2019.pdf
Type de publication	journal article
Type de publication	ACL
Domaine	Aucun
PMCID	PMC6351558
Fonction	aut
Audience	Non spécifiée
URL	https://univoak.eu/islandora/object/islandora:90355